GeoVax Labs Inc

GeoVax Labs has requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination it received on August 27, 2026, tied to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), with the hearing scheduled for October 13, 2026. The hearing request has stayed any suspension or delisting action pending the hearing and any extension period the Panel may grant, so GeoVax's common stock is expected to continue trading on The Nasdaq Capital Market under the symbol GOVX at least through that period. At the hearing, the company intends to present its plan to regain and maintain compliance with applicable Nasdaq listing standards. Chairman and Chief Executive Officer David Dodd said the Nasdaq process does not change GeoVax's strategic priorities, and that the company continues to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue manufacturing and global preparedness opportunities, and engage potential strategic, funding and development partners. GeoVax's priority program, GEO-MVA, is an investigational Modified Vaccinia Ankara-based vaccine targeting mpox and smallpox, and in oncology the company is developing Gedeptin, a gene-directed enzyme prodrug therapy that has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer.